TITLE

Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence

AUTHOR(S)
Shimatani, Tomohiko; Hirokawa, Seiko; Tawara, Yumiko; Hamai, Kazuko; Matsumoto, Mutsuko; Tazuma, Susumu; Inoue, Masaki
PUB. DATE
November 2009
SOURCE
Digestive Diseases & Sciences;Nov2009, Vol. 54 Issue 11, p2385
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Generic drugs contain the same active ingredient as an original drug and have their bioequivalence proved by pharmacokinetic tests. However, few studies have been reported on whether these bioequivalence studies infer pharmacodynamic equivalence. In this study, in eight healthy Helicobacter pylori-negative CYP2C19 extensive metabolizers, we compared the acid-suppressive effects of repeated administration of 15 mg of three brands of generic lansoprazole, Taiproton, Tapizol, and Lansoral, with those of the original lansoprazole, Takepron. Median intragastric pH value for 24-h and % pH > 4 for daytime (08:00-20:00 h) and night-time were significantly higher with any lansoprazole formulation, compared with the control (P < 0.05, Wilcoxon signed-rank test). However, during the daytime, % pH > 4 with Tapizol was significantly lower than the original (P < 0.05). Compared with the original, no significantly larger, but no small range of inter-subject variations were observed in these two parameters for each of the three brands of generic lansoprazole (Bartlett test). Pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence.
ACCESSION #
44645831

 

Related Articles

  • Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. Semino-Mora, Cristina; Doi, Sonia Q.; Marty, Aileen; Simko, Vlado; Carlstedt, Ingemar; Dubois, Andre // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1165 

    Gastric intestinal metaplasia (IM) and gastric cancer are associated with Helicobacter pylori, but the bacterium often is undetectable in these lesions. To unravel this apparent paradox, IM, H. pylori presence, and the expression of H. pylori virulence genes were quantified concurrently using...

  • Helicobacter pylori persistence: biology and disease. Blaser, Martin J.; Atherton, John C. // Journal of Clinical Investigation;Feb2004, Vol. 113 Issue 3, p321 

    Helicobacter pylori are bacteria that have coevolved with humans to be transmitted from person to person and to persistently colonize the stomach. Their population structure is a model for the ecology of the indigenous microbiota. A well-choreographed equilibrium between bacterial effectors and...

  • Mutation of the Cyba gene encoding p22phox causes vestibular and immune defects in mice. Nakano, Yoko; Longo-Guess, Chantal M.; Bergstrom, David E.; Nauseef, William M.; Jones, Sherri M.; Bánfi, Botond; Bánfi, Botond // Journal of Clinical Investigation;Mar2008, Vol. 118 Issue 3, p1176 

    In humans, hereditary inactivation of either p22(phox) or gp91(phox) leads to chronic granulomatous disease (CGD), a severe immune disorder characterized by the inability of phagocytes to produce bacteria-destroying ROS. Heterodimers of p22(phox) and gp91(phox) proteins constitute the...

  • Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Matsukura, Norio; Tajiri, Takashi; Kato, Shunji; Togashi, Akiyoshi; Masuda, Gotaro; Fujita, Itsuo; Tokunaga, Akira; Yamada, Nobutaka // Gastric Cancer;Jun2003, Vol. 6 Issue 2, p100 

    Background. The remnant stomach after surgery for gastric cancer is at high risk for the metachronous development of multiple gastric cancers. Here, we report on eradication therapy of Helicobacter pylori in the remnant stomach, comparing the eradication rate with that in unoperated stomachs. We...

  • Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication? Rakici, Halil; Akdogan, Remzi Adnan; Ayaz, Teslime; Bedir, Recep // Gastroenterology Research & Practice;3/15/2015, Vol. 2015, p1 

    Aim. We designed this trial to find answers to the following questions. (1) Does the success rate decrease in a country where HP prevalence is high? (2) Can we provide benefit by simultaneously treating the partners of infected patients? Materials and Methods. The first group consisted of 102...

  • A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Yoshida, K.; Sanada, M.; Kato, M.; Kawahata, R.; Matsubara, A.; Takita, J.; Shih, L.-Y.; Mori, H.; Koeffler, H. P.; Ogawa, S. // Leukemia (08876924);Jan2011, Vol. 25 Issue 1, p184 

    A letter to the editor is presented regarding the mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) in a series of cases with myelodysplastic syndrome (MDS).

  • Editorial: Sequential Therapy for Eradication of Helicobacter pylori: A New Guiding Light or a False Dawn? Moayyedi, Paul; Malfertheiner, Peter // American Journal of Gastroenterology;Dec2009, Vol. 104 Issue 12, p3081 

    Helicobacter pylori–related diseases are a major global problem, and currently recommended regimens are achieving disappointing eradication rates. Trials of sequential therapy have suggested that it is superior to standard proton pump inhibitor (PPI)-based triple therapy. Gatta et al....

  • Effect of Proton Pump Inhibitors on Gastric Juice Volume, Gastric pH and Gastric Intramucosal pH in Critically Ill Patients:A Randomized, Double-Blind, Placebo-Controlled Study. Gursoy, Olcay; Memiş, Dilek; Sut, Necdet // Clinical Drug Investigation;2008, Vol. 28 Issue 12, p777 

    Objective: This study aimed to determine the effect of administration of a single-dose proton pump inhibitor (PPI) on gastric intramucosal pH (pHi), gastric juice volume and gastric pH in critically ill patients. Methods: This prospective, randomized, double-blind, placebo-controlled study...

  • Labeling of omeprazole with technetium-99 m for diagnosis of stomach. Sanad, M. // Radiochemistry;Nov2013, Vol. 55 Issue 6, p605 

    Omeprazole, a proton pump inhibitor, was labeled with Tc to obtain Tc-omeprazole in ∼96% yield in basic media. The optimum conditions were as follows: pH 9, 50 μg of SnCl·2HO, 30 min, and 3 mg of the substrate. Tc-omeprazole was stable for 6 h. Intravenous biodistribution of...

  • Sensibilidad de la biopsia gástrica en la detección de Helicobacter pylori en pacientes en tratamiento con inhibidores de la bomba de protones. Azaña, Daisy; Egoavil, Miguel; Soto, Leslie; de los Rios, Raul // Revista Medica Herediana;ene-mar2012, Vol. 23 Issue 1, p11 

    Objective: To evaluate the sensitivity of gastric biopsy in detecting Helycobacter pylori (Hp) infection among patients who received proton pump inhibitors (PPI) 7-14 days before endoscopy compared to those who did not received PPI or who received a different medication. Methods: Case series....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics